AVL9

Across TCGA pan-cancer cohorts, AVL9 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of AVL9’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where AVL9 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types AVL9 is over-expressed in tumor.

HNSC, LUAD, and BLCA are the cancer types where AVL9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AVL9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.873	<.001	12	view →
LUAD	Male	II,III,IV	+1.550	<.001	11	view →
BLCA	Male	III,IV	+0.961	<.001	11	view →
LIHC	Female	II,III,IV	+0.984	<.001	9	view →
KIRP	All	All	+0.590	<.001	9	view →
STAD	Male	II,III,IV	+1.182	<.001	8	view →
LUSC	Male	II,III,IV	+0.723	<.001	7	view →
BRCA	All	II,III,IV	+0.777	<.001	6	view →
UCEC	All	II,III,IV	+0.719	.010	6	view →
COAD	Male	All	+0.580	<.001	6	view →
CHOL	Male	All	+1.810	<.001	3	view →
READ	All	III,IV	+0.695	.049	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

AVL9–HNSC

Open the HNSC breakdown →